Evident Vascular Announces Series B Financing

Gunderson Dettmer represented client Evident Vascular, a medical technology company developing a best-in-class intravascular ultrasound (IVUS) platform powered by artificial intelligence, in the announcement of its Series B financing from Shangbay Capital, Vensana Capital and more. Evident Vascular’s platform is designed to optimize vascular imaging for peripheral and coronary interventions. The new capital will help accelerate the company’s IVUS technology and support 510(k) FDA clearance ahead of U.S. market launch.

In the announcement of the transaction, CEO and Co-founder of Evident Vascular Howard Rosen said, “This significant investment underscores our investors' confidence in Evident Vascular’s mission and technology while highlighting the vital role of intravascular imaging in optimizing patient outcomes, clinical decision-making and procedural success. We will accelerate our progress toward FDA clearance and further the development of our AI-powered IVUS solution, which aims to set a new standard in vascular image guided therapy.”

The Gunderson deal team was led by Rich Hesp and included Morgan Clarke and Tyler Vandre.

Companies
Evident Vascular
Shangbay Capital
Vensana Capital